Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Buys 3,200 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 3,200 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were purchased at an average cost of $11.12 per share, with a total value of $35,584.00. Following the completion of the acquisition, the chief executive officer now owns 5,539,302 shares in the company, valued at approximately $61,597,038.24. This represents a 0.06 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Greenwich LifeSciences Price Performance

Shares of GLSI stock opened at $12.88 on Friday. The firm has a market cap of $169.37 million, a P/E ratio of -16.10 and a beta of 1.61. Greenwich LifeSciences, Inc. has a 1-year low of $8.00 and a 1-year high of $21.44. The firm has a fifty day moving average of $13.20 and a two-hundred day moving average of $14.20.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. State Street Corp grew its holdings in Greenwich LifeSciences by 4.4% during the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after acquiring an additional 3,005 shares in the last quarter. Geode Capital Management LLC grew its holdings in Greenwich LifeSciences by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after acquiring an additional 5,861 shares in the last quarter. Barclays PLC grew its holdings in Greenwich LifeSciences by 323.3% during the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after acquiring an additional 6,538 shares in the last quarter. Rhumbline Advisers acquired a new position in Greenwich LifeSciences during the 2nd quarter worth $117,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Greenwich LifeSciences in the 2nd quarter worth about $264,000. 4.16% of the stock is owned by institutional investors and hedge funds.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.